Indium In-111 Pentetreotide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Indium In-111 Pentetreotide. Educational only — not medical advice.
Labeled uses
Octreoscan, after radiolabeling, is an agent for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors.
Source: FDA labeling via NIH DailyMed (set 93d8f3b2…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.